Dr. Kurtz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Mayo Clinic College of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2010 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 8 citationsCAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.Mark P Hamilton, Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis
Blood Advances. 2024-06-25 - 3 citationsQuantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.Tej D Azad, Shigeki Nanjo, Michael C Jin, Jacob J Chabon, David M Kurtz
NPJ Precision Oncology. 2024-05-28 - 2 citationsNGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.Ehsan Tabari, Alexander F Lovejoy, Hai Lin, Christopher R Bolen, Seng Lor Saelee
Leukemia & Lymphoma. 2024-05-01
Abstracts/Posters
- An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell LymphomaDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel TherapyDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCLDavid M. Kurtz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma PatientsDecember 5th, 2024- Foresight Diagnostics and Leading Global Cancer Center to Present New Data on Foresight CLARITY™ Ultra-Sensitive MRD Detection in Early-Stage Breast Cancer at the 2024 San Antonio Breast Cancer SymposiumNovember 25th, 2024
- Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin LymphomaDecember 13th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
